Biocon sees larger licensing income from pharma

23001 Investors following Biocon. Share this News with them.

0

Like this story, share it with millions of investors on M3

Biocon sees larger licensing income from pharma

Biocon, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ News and Notices about Biocon See interviews with Biocon Management See what other Experts & Brokerages are saying about Biocon See previous Results of Biocon Biocon BSE | NSE 01/06/12 Are Mutual Funds betting on Biocon?

Biocon , India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.

The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8% in December quarter, while revenue rose 3%.

The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income, Kiran Mazumdar-Shaw, told a television channel.

The company said, licensing fees and income dropped to Rs 29.2 crore in October-December from Rs 76.8 crore a year earlier.